When was Proneuron Biotechnologies founded?

Proneuron Biotechnologies was founded in 1996 and raised its 1st funding round 1 year after it was founded.

Where is Proneuron Biotechnologies located?

Proneuron Biotechnologies is headquartered in New York City, United States.

How many employees does Proneuron Biotechnologies have?

As of Mar 31, 2026, the latest employee count at Proneuron Biotechnologies is 1.

Is Proneuron Biotechnologies a funded company?

Proneuron Biotechnologies is a funded company, having raised a total of $37.1M across 7 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on 1997.

When was the latest funding round of Proneuron Biotechnologies?

Proneuron Biotechnologies' latest funding was a $***** Grant (prize money) round on Jan 21, 2009, with participation from 1 investor.

Where does Proneuron Biotechnologies rank among its competitors?

Proneuron Biotechnologies ranks 1070th amongst 2803 active competitors, of which 968 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Proneuron Biotechnologies - 2026 Company Profile, Funding & Competitors

Q: Who are the top competitors of Proneuron Biotechnologies?

Proneuron Biotechnologies' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Proneuron Biotechnologies is a deadpooled company based in New York City (United States), founded in 1996. It operates as a Developer of therapies for spinal cord injury and other neurological conditions. Proneuron Biotechnologies has raised $37.1M in funding. The company has 2803 active competitors, including 968 funded and 694 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Website: proneuron.com
Email ID: *****@proneuron.com
Phone Number: +1 **********

Key Metrics

Founded Year

1996

Location

New York City, United States

Stage

Deadpooled

Total Funding

$37.1M in 7 rounds

Latest Funding Round

Grant (prize money), Jan 21, 2009, $*****

Investors

Swanlaab Venture Factory & 8 more

Ranked

1070^th among 2803 active competitors

Employee Count

1 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 542 more

View Proneuron Biotechnologies' full profile

Proneuron Biotechnologies has raised a total funding of $37.1M over 7 rounds. Its first funding round was on 1997. Its latest funding round was a Grant (prize money) round on Jan 21, 2009 for $*****. 1 investor participated in its latest round. Proneuron Biotechnologies has 9 institutional investors.

Here is the list of recent funding rounds of Proneuron Biotechnologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 21, 2009	5459782	Grant (prize money)	8884810	8411254	9225903	2035111
Jan 27, 2007	8958389	Grant (prize money)	7917354	4022375	8093181	The Michael J. Fox Foundation
Jul 11, 2004	7487689	Series B	7911705	1363175	6843207	Tamir Fishman

Access funding benchmarks and valuations. Sign up today!

View details of Proneuron Biotechnologies's funding rounds and investors

Proneuron Biotechnologies' employee count trend

Proneuron Biotechnologies has 1 employees as of Mar 26. Here is Proneuron Biotechnologies's employee count trend over the years:

Employee count trend for Proneuron Biotechnologies

Uncover Proneuron Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proneuron Biotechnologies include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Proneuron Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
1070th	Proneuron Biotechnologies 1996, New York City (United States), Deadpooled	Developer of therapies for spinal cord injury and other neurological conditions	$37.1M	Swanlaab Venture Factory, Giza Venture Capital ... & 7 others	37/100